Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Broader pipeline and earlier approvals
Neil highlights other approvals like Nulibri, Gondola Bio holdings, and ambitions to scale more rare-disease medicines.
Play episode from 01:05:11
Transcript
